- Suppliers
ADM 
Antares 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Captisol 
Clariant 
Croda 
DFE Pharma 
Dow 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
Kerry 
KLK Oleo 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
pharm-a-spheres 
PMC Isochem 
PQ 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma 
All4Nutra
- Suppliers
ADM Antares Armor Pharma Asahi KASEI Ashland BASF Beneo Captisol Clariant Croda DFE Pharma Dow Excipio Chemicals Fuji Chemical Gattefossé Gangwal IOI Oleo Ingredient Pharm JRS Pharma Kerry KLK Oleo Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts pharm-a-spheres PMC Isochem PQ Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma - All4Nutra
Overview Live Pharmaceutical Webinars and Webinar Recordings
Webinare-Startseite
5th Seminar on Amorphous Solid Dispersion
From Insights to Impact: Latest Advances in ASD
From Insights to Impact: Latest Advances in ASD
MORE INFORMATION & REGISTRATION
We are glad to announce the 5th Seminar on Amorphous Solid Dispersion. As technology provider in the field of ASD, Shin-Etsu together with the partners Alexanderwerk, Frewitt, PROCEPT and Thermo Fisher Scientific, will share latest insights of ASD development steps ranging from initial screening phase up to downstream processing including spray drying, hot melt extrusion (HME), roller compaction and milling.
The program is comprised of practical lab demonstrations of the different processing technologies featuring the prime polymer for ASDs, Shin-Etsu AQOAT® (HPMCAS), and lectures of invited experts of the field. Do not miss out on this two day seminar!
For more details please download the Seminar flyer here.
Topics:
- Recent developments in Screening Techniques
- Advances in Key Technologies: HME and Spray Drying
Lectures
Experts from academia and pharmaceutical companies Demonstrations:
- Spray Drying – Roller Compaction of Spray Dried Powders
- Hot Melt Extrusion – Milling of Extrudates
Target group
Research and development teams from the pharma industry looking for deeper information on ASD technologies
Location
Courtyard Marriot Wiesbaden, SE Tylose GmbH Wiesbaden
Registration
- Participation fee 950 €, VAT exempt
- Including meeting package, excluding accomodation
- Number of participants limited to 30
Date & Time & Timezone
- 23rd– 24th September 2026, CEST Amsterdam, Berlin, Rome, Stockholm, Vienna
For more information & registration here:
Prof. Dr. Gabriele Sadowski
TU Dortmund, Germany
“How coating materials may compromise the stability of ASDs”
Dr. Sune Klint Andersen
Johnson & Johnson
“Seeing Beyond the Surface: Advanced Characterization of Pharmaceutical Powders”
Lise Vandevivere
Xedev
“Tabletting of spray dried ASD powder: from early phase screening to optimized downstream processing”
Matthias Degenhardt
AbbVie
“Strategy and Tools to Design a robust Amorphous Solid Dispersion Formulation – Part I”
Also joining are:
- Dr. Christian Lübbert, Founder, AMOFOR, “Understanding Drug Release and Precipitation Risk in HPMCAS-Based Amorphous Solid Dispersions”
- Dr. Ines Ramos, Hovione, “Scale-up and downstream processing of amorphous solid dispersions by spray drying”
- Carolina Alva, RCPE, “High drug loaded HPMCAS ASDs, the rheological properties of them related to HME”
- Mitsuo Ishimaru, Shin-Etsu, “Can Wet Granulation Open New Possibilities for ASD?””
- Stefanie Walter, Abbvie, “Strategy and Tools to Design a robust Amorphous Solid Dispersion Formulation – Part II”
When lipids go solid: process strategies to enhance bioavailability in oral dosage forms
When lipids go solid: process strategies to enhance bioavailability in oral dosage forms
MORE INFORMATION & registration
Lipid excipients have a proven history of enhancing bioavailability of drugs through the improvement of the solubility, the permeability, and the absorption. Being often liquid at room temperature, they are mainly formulated in liquid forms, like in soft or in hard capsules. That said, oral solid dosages forms such as tablets, could benefit from the advantages of lipid excipients.
Gattefossé will highlight different processes to incorporate lipid excipients in oral tablets or powders, during a webinar which will include the following topics:
- Benefits of lipid excipients for bioenhancement,
- Market references,
- Case studies highlighting formulation strategies and associated manufacturing.
Date & Time & Timezone:
- Tue, Jun 30, 2026, 9:30 AM – 10:30 AM CEST Amsterdam, Berlin, Rome, Stockholm, Vienna
or - Tue, Jul 7, 2026, 11:30 AM – 12:30 PM CEST Amsterdam, Berlin, Rome, Stockholm, Vienna
For more information & registration here:
Recorded Webinars:
Smarter Stabilization for Lipid Nanoparticles: Formulating Biopharmaceuticals with Sucrose
Optimizing Pharmaceutical Formulations: Strategies for Improving Stability and Minimizing Impurities
Rethinking the development of controlled release formulations and manufacturing processes
Rational Selection of Cyclodextrins for the Solubilization of Poorly Soluble Oral Drugs
Solving capping challenges using mannitol as an excipient model
Development of directly compressible formulations of Sitagliptin hydrochloride and Sitagliptin phosphate.
Antioxidants, a safe and viable Inhibition Strategy for Nitrosamine Formation In Drug Products
Rational Selection and Application of Ready-to-Use Formulations for Self-Emulsifying Drug Delivery Systems
Glatt: Pellets from fluid bed processes – a smart concept for high(er) potent drug processing
From powder to DC oral solid dosage form – using galenIQ™, the sweet-tasting filler binder.
Solving one of the biggest limitations of modern clinical trials: Patient Recruitment
Multiparticulates Part 8: Scale up considerations on the Wurster (bottomspray) fluidized bed process
Multiparticulates – modern oral drug products for our society; Part 6: DoE case studies in QbD development
Don’t Feed the Trolls – Crazy Powders and Electrostatic Charge in Continuous Manufacturing
Multiparticulates 5 – Product and process development applying QbD and DoE concepts to define DS
Addressing Raw Material Handling Challenges by Dry Granulation
Rx & OTC Product Line Extensions with Oral Lipid-Based Delivery Platforms
Merck: 3D Printing – shaping the future of formulation development
Multiparticulates 4b – Glatt Fluidbed Wurster Drug Layering and Coating – the Process
Multiparticulates Part IVa: Functional Coating Applications – The Basics
Multiparticulates for paediatric oral drug delivery
Neutral And Functional Starter Pellets
The Easy Way Of Tableting: Excipient Premixes For Direct Compression
Multiparticulates From Matric Core Pellets – Glatt CPS® Technology
Market Trends & Clean Label Solutions for Solid Oral Dosage Forms
Multiparticulates As Modern Oral Drug Products
Multiparticulates Part III: Multiparticulates From Matrix Core Pellets – Glatt MicroPx And ProCell Technology
Innovative Technologies For Amorphous Solid Dispersions
A beginners guide to SELF’ies for solubility and oral bioavailability enhancement
